Key clinical point: For patients with relapsed/refractory chronic lymphocytic leukemia, long-term treatment with idelalisib appears safe and effective.
Major finding: Patients who received a combination of rituximab and idelalisib followed by idelalisib monotherapy had a median overall survival of 40.6 months.
Study details: A randomized, double-blind, phase 3 trial involving patients with relapsed/refractory chronic lymphocytic leukemia.
Disclosures: Gilead Sciences funded the study. Dr. Sharman reported financial relationships with Gilead and other companies.
Sharman JP et al. J Clin Oncol. 2019 Apr 17. doi: 10.1200/JCO.18.01460.